PRAME transcript expression in MM patients during chemotherapy.
RNA samples collected from patients MM1, 4, and 6 at diagnosis and during treatment were analyzed for
PRAME expression using the
PRAME/
ABL qRT-PCR assay. The normalized ratios were plotted along with the previously collected normalized
MAGEC1 data [
21] and serum M and Sb2M levels. *Indicates patient death within three months of the last data point; C+D, cyclophosphamide/dexamethasone cycles; M+P, melphalan/prednisone cycles; R, localiszd radiation; open circles indicate a lack of detectable transcripts at a sensitivity level determined by the corresponding
ABL Cq.|@|~(^,^)~|@|
MAGEA3 transcript expression in MM patients during chemotherapy.
RNA samples collected from patients MM 3, 8, and 10 at diagnosis and during treatment were analyzed for
MAGEA3 expression using the
MAGEA3/
ABL qRT-PCR assay. The normalized ratios were plotted along with the previously collected normalized
PRAME data,
MAGEC1 data [
21], and serum M levels. *Indicates patient death within three months of the last data point; C+D, cyclophosphamide/dexamethasone cycles; R, localized radiation. Open circles indicate a lack of detectable transcripts.|@|~(^,^)~|@|
BAGE2 transcript expression in MM patients during chemotherapy.
RNA samples collected from patients MM 6, 8, and 9 at diagnosis and during treatment were analyzed for
BAGE2 expression using the
BAGE2/
ABL qRT-PCR assay. The normalized ratios were plotted along with the previously collected normalized
MAGEA3,
PRAME, and
MAGEC1 data and serum M/Sβ
2M levels. *Indicates patient death within three months of the last data point; colored arrows indicate the date of associated transcript increase, showing a succession pattern; Crt, creatinine mmol/l; Hb, hemoglobin g/dL; open circles indicate a lack of detectable transcript.|@|~(^,^)~|@|Schematic of the proposed evolution of MM clones based on the expression of a CTA cascade.